Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer

Andrée Boucher, Shereen Ezzat, Sebastien Hotte, Irina Rachinsky, Murali Rajaraman, Dean Ruether, Sam M. Wiseman, James Brierley, Cheryl Ho, Monika Krzyzanowska, Nathan Lamond, Marie Hélène Massicotte, Shereen Joseph, Kassey Herscovitch, Lindsey Sikora, Eric Winquist

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Radioactive iodine-resistant differentiated thyroid cancer (RAIRTC) is an aggressive form of thyroid cancer that is uncommon and heterogeneous in its clinical behavior. With the emergence of more effective systemic therapy, the need for guidance in decision-making was recognized and a consensus committee of national experts was assembled. The consensus committee consisted of 13 clinicians involved in treating RAIRTC from across Canada and included endocrinologists, nuclear medicine physicians, surgeons, and radiation and medical oncologists. Domains of interest were identified by consensus, and evidence gathered using systematic reviews. Consensus recommendations for the diagnosis and management of RAIRTC were developed. It was recognized that the rarity of RAIRTC in practice and heterogeneous patterns of thyroid cancer care could limit access to effective therapy for some RAIRTC patients. This document offers guidance to manage RAIRTC patients in a multidisciplinary manner.

Original languageEnglish
Article number105477
JournalOral Oncology
Volume121
DOIs
StatePublished - 1 Oct 2021
Externally publishedYes

Keywords

  • Differentiated thyroid cancer
  • Head and Neck Neoplasms
  • Iodine Radioisotopes
  • Lenvatinib
  • Protein Kinase Inhibitors
  • Radioactive iodine
  • Refractory
  • Resistant
  • Sorafenib
  • Thyroid Neoplasms

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer'. Together they form a unique fingerprint.

Cite this